Orgenesis Inc is a company driven by values and a corporate philosophy focused on advancing cell and gene therapy. They are committed to improving patient outcomes through innovative technologies and solutions. With a patient-centric approach, Orgenesis aims to transform the traditional treatment methods by developing personalized therapies that provide long-term benefits. By collaborating with leading experts in the field, they strive to accelerate the development of breakthrough treatments and enhance the accessibility of cell therapy. As an organization, Orgenesis promotes transparency, integrity, and responsible business practices. Their commitment to scientific excellence and patient well-being sets them apart in the industry.

Orgenesis Inc is primarily present in multiple countries and regions worldwide. The company has established a significant presence in the United States, Belgium, Israel, China, and South Korea. With its global expansion efforts, Orgenesis Inc aims to leverage local resources and partnerships to enhance its presence and capture opportunities in key international markets. The company's presence across these countries and regions reflects its commitment to advancing cell and gene therapies, as well as its strategic focus on growing its business globally.

Orgenesis Inc has achieved several significant milestones in its history. One notable achievement for the company was the development of its breakthrough therapeutic platform, which enables the conversion of liver cells into fully-functional, insulin-producing cells for the treatment of diabetes. This innovative technology has shown promising results in both pre-clinical and clinical studies, positioning Orgenesis Inc as a leader in the field of regenerative medicine. Additionally, the company has successfully entered into strategic partnerships and collaborations, strengthening its global presence and opening up new avenues for growth and development. These milestones highlight Orgenesis Inc's commitment to revolutionizing healthcare through cutting-edge solutions and strategic alliances in the biotech industry.

Orgenesis Inc, based in Germantown, Maryland, is a leading biotechnology company focused on the development and commercialization of therapeutic products and technologies for advanced cell and gene therapies. Founded in 2008, the company has a rich history in the field of regenerative medicine. Orgenesis specializes in the development of autologous cell-based therapies, which involve using a patient's own cells to create personalized treatments for a range of diseases, including diabetes and liver diseases. With a strong commitment to innovation and collaboration, Orgenesis continues to make significant strides in advancing the field of regenerative medicine and improving patients' lives worldwide.

Orgenesis Inc faces competition from various companies in the market. Some of the main competitors include Tissue Regenix Group, Medtronic plc, Organogenesis Holdings Inc, Integra LifeSciences Holdings Corporation, and Vericel Corporation.

Orgenesis Inc is primarily active in the biotechnology and life sciences industry.

Orgenesis Inc operates with a unique business model focused on advanced cell therapy development and transformative regenerative medicine. The company specializes in developing and manufacturing innovative, autologous cell therapies to address unmet medical needs, particularly in the field of diabetes. By leveraging its proprietary technology platforms, Orgenesis provides personalized medicine solutions that involve collecting and utilizing a patient's own cells for therapeutic purposes. This approach allows for more effective and safer treatments, leading to improved patient outcomes. Overall, Orgenesis is dedicated to revolutionizing the healthcare industry by harnessing the potential of regenerative medicine and advancing personalized cell therapies.

Коефициентът на цена спрямо печалбата (КЦП) на Orgenesis е 0,59.

Коефициентът на цена към оборот (KUV) на Orgenesis е 0,24.

AlleAktien качественият резултат за Orgenesis е 6/10.

очаквана Orgenesis оборотът е 71,71 млн. USD.

очаквана Orgenesis печалба е 29,20 млн. USD.

Orgenesis Inc is a global biotechnology company that focuses on the development and commercialization of drugs for the treatment of diabetes and other metabolic diseases. The company operates through various divisions, including the hearing aid division, the cell therapy division, and the pharmaceutical division. The hearing aid division of the company focuses on the development, manufacturing, and marketing of hearing aids that help individuals with hearing loss. The hearing aids contain the latest technologies to improve sound quality and minimize background noise. The company offers a wide range of hearing aids that meet the different needs of its customers. In the cell therapy division, Orgenesis develops and produces cells for the regenerative medicine industry that can be used to treat various diseases such as type 1 diabetes, liver and lung diseases, and cancer. The company uses its proprietary platform technology to transform stem cells into specific, differentiated cell types that can contribute to the regeneration of affected tissues in the body. The pharmaceutical division of the company focuses on the development and commercialization of drugs for the treatment of diabetes and other metabolic diseases. Orgenesis has developed a platform technology that allows for the conversion of human cells into insulin-producing cells that help the body regulate its blood sugar levels. The company has also developed a technology for the production of subcutaneous insulins specifically designed for patients with type 1 and type 2 diabetes. Through its various divisions, Orgenesis Inc offers a wide range of products and services tailored to the needs of its customers. The company relies on a comprehensive research and development strategy to develop innovative technologies and solutions for the treatment of diabetes and other diseases. Orgenesis Inc pursues a partnership-based business model to expand its product portfolio and accelerate growth. The company collaborates with leading players in the regenerative medicine and pharmaceutical industries to market its products and technologies on a global scale. In collaboration with the University of Louisville in Kentucky, Orgenesis has established its own cadaver pancreas collection to research new approaches to the production of subcutaneous insulins. In March 2020, the company committed to a strategic focus on Advanced Therapy Medicinal Products (ATMP). The ATMP portfolio innovation is intended to be achieved through the company's acquisition of MaSTherCell in 2019, a therapist-led company specializing in the development of cell therapies from the research pipeline to the commercialization of drugs. Orgenesis' primary approach is to offer its customers high-quality, safe, and effective products that bring value to their lives. The company strives to be a leader in the biotechnology industry by developing innovative products and technologies that improve the quality of life for patients worldwide.

Orgenesis разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Orgenesis в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Orgenesis е US68619K2042.

WKN на Orgenesis е A2H7XQ.

Тикерът на Orgenesis е ORGS.

През последните 12 месеца Orgenesis изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Orgenesis да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Orgenesis в момента е .

Orgenesis изплаща дивидент на тримесечие. Той се разпределя в месеците .

Orgenesis платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Orgenesis се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Orgenesis на 7.09.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 7.09.2024 г..

Последното дивидентно плащане беше извършено на 7.09.2024 г..

През година 2023 Orgenesis изплати 0 USD под формата на дивиденти.

Дивидентите от Orgenesis се изплащат в USD.